An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors.

Trial Profile

An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2014

At a glance

  • Drugs Carotuximab (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 May 2013 Results will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top